---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2013122323281823.pdf）的“原文Prescribing Information”为准
---------------------------------------------------------------
部分中文mirabegron处方资料（仅供参考）

   美国FDA批准了mirabegron(米拉贝隆)治疗成人膀胱过度活动症。该药是每日服一次的缓释片,本品剂量规格：25毫克 100片.由Astellas公司出品,可选择性地与膀胱肌肉的β3肾上腺素受体结合并将其激活

Mirabegron(Betanis)是由Astellas公司开发的口服有效的新型选择性β3肾上腺素能受体激动剂,已在日本首次获推荐批准,用于治疗膀胱过度活动症(OAB),且也已在欧美递交上市申请。与目前常用的OAB治疗药,如抗胆碱能药物托特罗定和索利那新等通过阻止乙酰胆碱与受体结合而减弱

Betanis tablet is a once daily oral selective β3-adrenoceptor agonist discovered and developed by Astellas. Betanis tablet enhances the urine collection function by activating β3-adrenoceptor selectively on the bladder’s smooth muscles and relaxing bladder, and improves symptoms associated with OAB such as urgency, urinary frequency, and urge urinary incontinence.

PRODUCT SUMMARY Product name: Betanis® tablet 25mg/50mg

Generic name: mirabegron

Indication: Urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder

Dosage regimen

For oral use, the usual adult dosage is 50 mg of mirabegron once daily after meal

Betanis has a warning in its label to refrain from using in patients of reproductive age wherever possible based upon findings in animal studies (rat).